FDA Adverse Event Injury Summary report: N

POWERED LASER SURGICAL INSTRUMENT

MDR report key: 22403833 · Received July 4, 2025

Report

Report Number
2124215-2025-43481
Event Type
Injury
Date Received
July 4, 2025
Date of Event
February 1, 2025
Report Date
July 4, 2025
Manufacturer
LUMENIS LTD
Product Code
GEX
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IT
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

FANCELLO, V., DOLCI, C., TANDOI, I., SCHIMBERNI, M., BARTIROMO, L., SALMERI, N., DALESSANDRO, S. (2025). LONG-TERM POSTOPERATIVE RECURRENCE RATES AND FERTILITY OUTCOMES AFTER ENDOMETRIOMA CO2-LASER VAPORIZATION: A FIVE-YEAR FOLLOW-UP EXPERIENCE. THE JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY 32(2), 171-176. 10.1016/J.JMIG.2024.09.367.

Description of Event or Problem · 0

IT WAS REPORTED VIA AN ARTICLE PUBLISHED ON THE JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY THAT, A RETROSPECTIVE STUDY WAS CONDUCTED TO ASSESS POSTOPERATIVE RECURRENCE RATE AND PREGNANCY RATE IN PATIENTS WITH ENDOMETRIOMAS MANAGED BY CO2 FIBER LASER VAPORIZATION AFTER AT LEAST 5 YEARS FOLLOWING SURGERY. A TOTAL OF 78 PATIENT FROM AN ITALIAN TERTIARY CENTER FROM OCTOBER 2023 TO FEBRUARY 2024 WERE INCLUDED. THE MEAN AGE WAS 33 YEARS. THE CYST WALL WAS VAPORIZED WITH CO2 FIBER LASER (ULTRAPULSE DUO SYSTEM, LUMENIS LTD, YOKNEAM, ISRAEL) IN A RADIAL MANNER, STARTING FROM THE CENTER TO THE PERIPHERY AT A MEAN POWER DENSITY OF 13 W/CM2 (RANGE, 10 15). THE POSTOPERATIVE OUTCOMES INCLUDED HORMONAL THERAPY AFTER SURGERY, IPSILATERAL CYSTS RECURRENCE, RECURRENT ENDOMETRIOMA. CO2 FIBER LASER VAPORIZATION IS AN EFFECTIVE AND SAFE SURGICAL TREATMENT OF OVARIAN ENDOMETRIOMAS, COMBINING THE ADVANTAGE OF BEING AN OVARIAN TISSUE-SPARING TECHNIQUE WITH LONG-TERM POSTOPERATIVE RECURRENCE RATE COMPARABLE WITH THAT DESCRIBED IN LITERATURE FOR THE CYSTECTOMY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2763755 POWERED LASER SURGICAL INSTRUMENT GEX LUMENIS LTD

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown